This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
DNA methylation changes in cord blood and the developmental origins of health and disease – a systematic review and replication study
BMC Genomics Open Access 19 March 2022
-
Detecting cord blood cell type-specific epigenetic associations with gestational diabetes mellitus and early childhood growth
Clinical Epigenetics Open Access 26 June 2021
-
Estimands in epigenome-wide association studies
Clinical Epigenetics Open Access 29 April 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
14 March 2017
In the version of this article initially published, some numbers in Table 1 did not appear in boldface. In the HTML originally posted online, the author affiliation for Elior Rahmani was incorrect; Rahmani is affiliated with only the Tel-Aviv University, Israel. The Supplementary Information file has been replaced to correct for additional callouts of Supplementary Notes in the Supplementary Figure legends. The errors have been corrected in the HTML and PDF files as of 14 March 2017.
References
Zheng, S.C. et al. Nat. Methods 14, 216–217 (2017).
Rahmani, E. et al. Nat. Methods 13, 443–445 (2016).
Houseman, E.A. et al. BMC Bioinformatics 13, 86 (2012).
Leek, J.T. & Storey, J.D. PLoS Genet. 3, e161 (2007).
Teschendorff, A.E. et al. Nat. Commun. 7, 10478 (2016).
Koestler, D.C. et al. BMC Bioinformatics 17, 120 (2016).
Teschendorff, A.E., Zhuang, J. & Widschwendter, M. Bioinformatics 27, 1496–1505 (2011).
Tan, Q. et al. BMC Genomics 15, 1062 (2014).
Liu, Y. et al. Nat. Biotechnol. 31, 142–147 (2013).
Hannon, E. et al. Genome Biol. 17, 176 (2016).
Acknowledgements
This research was partially supported by the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University, the Israel Science Foundation (1425/13 to E.R. and E.H.), US National Science Foundation grant 1331176 and United States Israel Binational Science Foundation grant 2012304 (to E.R., Y.B. and E.H.). E.R. was supported by Len Blavatnik and the Blavatnik Research Foundation. N.Z. was supported in part by a US National Institutes of Health (NIH) career development award from the NHLBI (K25HL121295). C.E., S.H., D.H., J.G., S.O. and E.G.B. were supported by the Sandler Family Foundation, the American Asthma Foundation, Hind Distinguished Professorships and NIH grants 1P60MD006902, 1R01HL117004, R21ES24844, R01Hl128439 and TRDRP 24RT-0025. E.E. was supported by NSF grants 1065276, 1302448, 1320589 and 1331176 and NIH grants R01-GM083198, R01-ES021801, R01-MH101782, R01-ES022282 and U54EB020403.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Evaluation of the number of expected spurious associations when using a small number of controls in EWAS.
The histogram of significant associations found across 100 EWAS experiments on the data used by Zheng et al. for constructing the gold standard list of “true positives”. The red line marks 23,258, the number of sites defined in the “true positives” list by Zheng et al.
Supplementary Figure 2 Capturing cell-type composition in breast cancer data using ReFACTor.
(a) A reconstruction of Figure S1 from Zheng et al., showing correlation of the cell-types and disease status (N/C) with each of the first 25 principal components of the data (n=355). Here, as well as in the following subfigures, the colors correspond to the logarithm of the P-values of the correlations. (b) The correlation of the first 25 ReFACTor components with the cell-types and disease status, as well as with the variation of the disease status that is independent of the cell composition (Adj. N/C). (c) The correlation of the first 25 SVA components (SVs) with the cell-types and with the unadjusted and adjusted disease status. (d) The mean R2 levels, across the nine estimated cell-types, of linear models fitted for each cell-type using an increasing number of ReFACTor component and using an increasing number of SVs. For any given number of components, ReFACTor has better R2 level than SVA.
Supplementary Figure 3 Capturing cell-type composition variation in the GALA II dataset.
(a)-(d) R2 values of the linear model predicting flow-cytometric estimates for blood cell-types, as a function of the number of ReFACTor components included in the model (blue data points and lines) for the GALA II dataset (n=84). Horizontal blue lines indicate the R2 values of the model using the ReFACTor components with significant likelihood ratio test (LRT) P-values (significant components are marked with squares). The reference-based estimates of the entire GALA II dataset (n=560) were used to determine the number of significant ReFACTor components. Horizontal orange lines indicate the performance of the reference-based method. (e) The mean R2 level over all cell-types.
Supplementary Figure 4 Capturing cell-type composition variation in the Koestler et al. dataset.
(a)-(f) R2 values of the linear model predicting flow-cytometric estimates for blood cell-types, as a function of the number of ReFACTor components included in the model (blue data points and lines) for the Koestler et al. dataset (n=18). Horizontal blue lines indicate the R2 values of the model using the ReFACTor components with significant likelihood ratio test (LRT) P-values (significant components are marked with squares). Horizontal orange lines indicate the performance of the reference-based method. (g) The mean R2 level over all cell-types.
Supplementary Figure 5 Performance for capturing cell-type composition in small data is highly variable.
(a) Sampling 100 subsets of 18 individuals with cell counts from the GALA II dataset (n=84) reveals that the performance (measured in mean R2 across all cell-types) of both ReFACTor and the reference-based method are highly variable due to the small number of samples used. (b) Distribution of the performance after sampling 100 subsets of 15 individuals from the Koestler et al. data (n=18).
Supplementary Figure 6 RMT estimates of the dimension in data as a function of the sample size.
The estimated dimensions by the RMT method (Teschendorff et al. 2011) as a function of the number of samples (each time adding a new randomly selected sample) using (a) the GALA II dataset (n=560), (b) a dataset by Liu et al. (n=686) and (c)-(d) two independent datasets by Hannon et al (n=675 and n=847). Linear regression lines (indicated in red) demonstrate a nearly perfect linear relation (P-value<10−93 in all plots).
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–6, Supplementary Tables 1–6, Supplementary Methods and Supplementary Notes 1–5 (PDF 720 kb)
Rights and permissions
About this article
Cite this article
Rahmani, E., Zaitlen, N., Baran, Y. et al. Correcting for cell-type heterogeneity in DNA methylation: a comprehensive evaluation. Nat Methods 14, 218–219 (2017). https://doi.org/10.1038/nmeth.4190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nmeth.4190
This article is cited by
-
DNA methylation changes in cord blood and the developmental origins of health and disease – a systematic review and replication study
BMC Genomics (2022)
-
Estimands in epigenome-wide association studies
Clinical Epigenetics (2021)
-
Detecting cord blood cell type-specific epigenetic associations with gestational diabetes mellitus and early childhood growth
Clinical Epigenetics (2021)
-
Epigenetic pacemaker: closed form algebraic solutions
BMC Genomics (2020)
-
Comparing DNA methylation profiles across different tissues associated with the diagnosis of pediatric asthma
Scientific Reports (2020)